Transcatheter aortic valve replacement outcomes in patients with low-flow very low-gradient aortic stenosis
European Heart Journal - Cardiovascular Imaging · 2024
DOI: 10.1093/ehjci/jead243 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal - Cardiovascular Imaging, 2024. Verfasst von Hiroki A Ueyama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029, USA. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Aims
In patients with severe aortic stenosis (AS), low-flow low-gradient (LG) is a known predictor of worse outcomes. However, very LG may represent a distinct population with further cardiac dysfunction. It is unknown whether this population benefits from transcatheter aortic valve replacement (TAVR). We aimed to describe the patient characteristics and clinical outcomes of low-flow very LG severe AS. Methods and results This single-centre study included all patients with low-flow severe AS between 2019 and 2021. Patients were divided into groups with very LG [mean pressure gradient (MPG) ≤ 20 mmHg], LG (20 < MPG < 40 mmHg), and high-gradient (HG) (MPG ≥ 40 mmHg). Composite endpoint of all-cause mortality and heart failure rehospitalization was compared. A total of 662 patients [very LG 130 (20%); LG 339 (51%); HG 193 (29%)] were included. Median follow-up was 12 months. Very LG cohort had a higher prevalence of comorbid conditions with lower left ventricular ejection fraction (45% vs. 57% vs. 60%; P < 0.001). There was a graded increase in the risk of composite endpoint in the lower MPG strata (P < 0.001). Among those who underwent TAVR, very LG was an independent predictor of the composite endpoint (adjusted HR 2.42 [1.29–4.55]). While LG and HG cohorts had decreased risk of composite endpoint after TAVR compared with conservative management, very LG was not associated with risk reduction (adjusted HR 0.69 [0.35–1.34]).
Conclusion
Low-flow very LG severe AS represents a distinct population with significant comorbidities and worse outcomes. Further studies are needed to evaluate the short- and long-term benefits of TAVR in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029, USA.
- Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, NY, USA.
- Division of Cardiology, Emory Structural Heart and Valve Center, Emory University Hospital Midtown, Atlanta, GA, USA.
ORCID-Profile: Samin K Sharma, Stamatios Lerakis
Zitieren
APA
Ueyama, H. A., Chopra, L., Dalsania, A., Prandi, F. R., Sharma, S. K., Kini, A., & Lerakis, S. (2024). Transcatheter aortic valve replacement outcomes in patients with low-flow very low-gradient aortic stenosis. European Heart Journal - Cardiovascular Imaging. https://doi.org/10.1093/ehjci/jead243
Vancouver
Ueyama HA, Chopra L, Dalsania A, Prandi FR, Sharma SK, Kini A, et al. Transcatheter aortic valve replacement outcomes in patients with low-flow very low-gradient aortic stenosis. European Heart Journal - Cardiovascular Imaging. 2024. doi:10.1093/ehjci/jead243
BibTeX
@article{Ueyama2024,
author = {Ueyama, Hiroki A and Chopra, Lakshay and Dalsania, Ankur and Prandi, Francesca Romana and Sharma, Samin K and Kini, Annapoorna and Lerakis, Stamatios},
title = {Transcatheter aortic valve replacement outcomes in patients with low-flow very low-gradient aortic stenosis},
journal = {European Heart Journal - Cardiovascular Imaging},
year = {2024},
doi = {10.1093/ehjci/jead243}
}
EUVIMED